Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of ($0.67), $0.17 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $14.35 million versus the consensus estimate of $17.4 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.